611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO, CA
Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
Quince Therapeutics Approves 2026 Equity Incentive and ESPP Plans
Resigning Directors: June Bray, David Lamond, and Christopher Senner
Unaudited Pro Forma Condensed Consolidated Financial Information
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
President Charles Ryan Departure Announcement - Quince Therapeutics, Inc.
Acquire Orphai Therapeutics, LLC
Reports Second Quarter 2026 Financial Results and Corporate Update
Q1
FY 2025
Notice of Late Filing for Annual Report
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload